Medication info
Linagliptin Metformin Duo Tablet 2.5/500 mg

Linagliptin Metformin Duo Tablet 2.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Bright yellow, bilaterally convex, film-coated tablet in a round shape
Packaging
10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box [(10 tablets/PTP×3)]
Approval status
Active

MFDS item code 201902757 · Approved 2019.04.29 · Insurance code 642906860

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, the insulin dose may need to be reduced to decrease the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antidiabetic drugs to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that could increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to help control blood sugar levels in patients with type 2 diabetes taking both linagliptin and metformin. It is used in conjunction with dietary and exercise therapy to effectively improve blood glucose levels. Therefore, this medication is used to enhance blood sugar control in type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, the insulin dose may need to be reduced to decrease the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antidiabetic drugs to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that could increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Precautions

This medication may cause serious side effects, such as lactic acidosis, so patients with poor kidney function or heart disease, or liver dysfunction should not use it. Additionally, patients with allergies to the ingredients of this medication or patients with type 1 diabetes, acute infections, or dehydration should not take it. There is a risk of hypoglycemia when used in conjunction with sulfonylureas or insulin, so caution is necessary, and blood glucose levels should be closely monitored. Kidney function should be regularly checked, and extra caution is necessary for elderly patients or those at risk for decreased kidney function. Rare side effects such as acute pancreatitis or bullous pemphigoid can occur, so if there are persistent and severe abdominal pains or blisters on the skin, a doctor should be informed immediately. Furthermore, vitamin B12 levels may decrease, thus regular blood tests are necessary during long-term use. This medication is not recommended for women who are pregnant or breastfeeding, and should be avoided if pregnancy is planned. Safety and effectiveness in children and adolescents have not been established, therefore those populations are discouraged from using this medication. It is advisable to avoid alcohol intake during the medication period, and potential interactions with other drugs should be discussed with a doctor or pharmacist. In case of overdose, there is a risk of lactic acidosis, and immediate medical treatment is required; the medication should be stored out of reach of children and kept away from moisture.

Side effects

Lactic acidosis, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular dermatosis, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficient vitamin B12, oral ulcers, hepatitis, abnormal liver function, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, pruritus, insomnia, depression, hypertension, erectile dysfunction, goiter, anxiety, mood disorder, contusion, bone contusion, concussion, bone fracture, hand fracture, laceration, palpitations, dry eyes, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, benign prostatic hyperplasia, confused state, nocturia, dermatitis, osteoarthritis, limb pain, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased triglycerides in the blood, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased potassium in the blood, increased creatinine in the blood, increased creatine phosphokinase in the blood, increased ALT, increased triglycerides in the blood, male pattern baldness, hyperhidrosis, hair loss, skin lesions, anxiety, insomnia, depression, hypertension, dizziness, benign prostatic hyperplasia, angina, acute myocardial infarction, unstable angina, diarrhea, pancreatitis, stomatitis, mediastinitis, pneumonia, rhinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, upper abdominal pain, anal bleeding, cheilitis, caries, enteritis, gastritis, stomatitis, dizziness, headache, drowsiness, chest discomfort, weakness, pain, epistaxis, oropharyngeal pain, voicing disorder, nasal bleeding, increased creatinine in the blood, facial edema, hyperthermia, back pain, flank pain, osteoarthritis, limb pain, rotator cuff syndrome, diabetic neuropathy, subdural effusion, corneal abrasion, falls, ligament sprain, upper limb fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and humidity and should be stored in a tightly sealed container. It is also important to keep it at room temperature between 1 degree to 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Bright yellow, bilaterally convex, film-coated tablet in a round shape

Package unit

10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box [(10 tablets/PTP×3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.